相关实验视频

Updated: Jan 9, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

阿尔特苏纳酸对布莱米辛诱导的肺纤维化的影响

Aysun Şengul¹, Oğuzhan Okutan², Bülent Altınsoy³

¹Department of Pulmonology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.

Acta clinica Croatica

|December 4, 2025

概括

在形肺纤维化 (IPF) 的大鼠模型中,阿特苏纳酸治疗显示出改善纤维化和炎症的潜力. 虽然它没有显著改善运动能力,但它减少了右心室缩和肺动脉动脉壁厚度.

科学领域:

肺部医学肺部医学
药理学药理学是指药理学的学科.
毒理学毒理学毒理学

背景情况:

异形性肺纤维化 (IPF) 是一种进展性肺部疾病,没有治愈方法.
目前的治疗方法有效性有限,需要对新型治疗剂进行研究.

研究的目的:

为了研究阿尔特苏纳酸对纤维化,肺高血压和炎症的治疗作用,在白血素诱导的IPF大鼠模型中.
评估阿尔特苏纳酸对运动能力,右心室缩和肺动脉动脉重塑的影响.

主要方法:

雄性威斯塔尔白色老鼠被分为四组:对照组,仅使用阿尔特苏纳酸,白素诱导的IPF,以及白素+阿尔特苏纳酸.
布莱米辛用于诱导肺纤维化,随后进行21天的阿尔特苏纳酸 (30毫克/千克/天) 或盐水治疗.
评估了运动能力,右心室缩 (RVH),肺动脉动脉壁厚度,纤维化和炎症标志物.

主要成果:

在白胺诱导的IPF大鼠中,阿特苏纳酸治疗显著降低了RVH (0.37±0.03对比0.44±0.02) 和肺动脉动脉壁厚度 (p<0.001).
在白素+阿尔特苏纳特组 (p<0.001) 观察到纤维化和炎症变化的显著改善.
虽然运动能力显示了群体间的差异 (p=0.001),但白素和白素+阿尔特苏纳特组之间没有发现显著差异 (p=0.95).

结论:

阿特苏纳酸通过改善纤维化,炎症,RVH和肺动脉状动脉结在白素诱导的肺纤维化小鼠模型中显示出治疗潜力.
需要进一步的研究来探索阿尔特苏纳酸作为治疗IPF的疗效.
阿尔特苏纳特可以提供一种新的治疗策略,用于管理IPF的关键病理特征.

关键词:

太阳的艺术布莱莫辛是一种白色素.异形性肺纤维化症异形性肺纤维化症右心室缩症是什么意思

更多相关视频

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...